Viral vector-based modeling of neurodegenerative disorders: Parkinson’s disease

Methods in Molecular Biology

Volumn 1382, Issue , 2016, Pages 367-382

  Fischer, D Luke ^a   Gombash, Sara E ^a   Kemp, Christopher J ^a   Manfredsson, Fredric P ^a   Polinski, Nicole K ^a   Duffy, Megan F ^a   Sortwell, Caryl E ^a  

^a NONE

Author keywords

Adeno associated virus; Dopamine; Lentivirus; Leucine rich repeat kinase 2; Lewy body; Parkin; Parkinson s disease; PTEN induced putative kinase 1; Striatum; Substantia nigra; Tyrosine hydroxylase; synuclein

Indexed keywords

VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; AGING; CONSTRUCT VALIDITY; LENTIVIRINAE; MURINE MODEL; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIMATE; VIRAL GENE THERAPY; ANIMAL; DEPENDOPARVOVIRUS; DISEASE MODEL; GENE THERAPY; GENE VECTOR; GENETICS; MOUSE; PATHOLOGY;

ANIMALS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GENETIC VECTORS; LENTIVIRUS; MICE; PARKINSON DISEASE;

EID: 84948809260     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-3271-9_26     Document Type: Chapter

References (94)

1. Pahwa R, Lyons KE (2013) Handbook of Parkinson’s disease. CRC, Boca Raton, FL, p. 14, 605 pages
2. Hirtz D et al (2007) How common are the “common” neurologic disorders? Neurology 68(5):326-337
3. Jankovic J (2008) Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79(4):368-376
4. Aminoff MJ (2001) Parkinson’s disease. Neurol Clin 19(1):119-128, vi
5. Pollanen MS, Dickson DW, Bergeron C (1993) Pathology and biology of the Lewy body. J Neuropathol Exp Neurol 52(3):183-191
6. Shults CW (2006) Lewy bodies. Proc Natl Acad Sci U S A 103(6):1661-1668
7. Wakabayashi K et al (2013) The Lewy body in Parkinson’s disease and related neurodegenerative disorders. Mol Neurobiol 47(2):495-508
8. Bendor JT, Logan TP, Edwards RH (2013) The function of alpha-synuclein. Neuron 79(6):1044-1066
9. Spieles-Engemann AL et al (2010) Stimulation of the rat subthalamic nucleus is neuroprotective following significant nigral dopamine neuron loss. Neurobiol Dis 39(1):105-115
10. Kordower JH et al (2013) Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain 136 (Pt 8): 2419-2431
11. Mogi M et al (1994) Interleukin-1 beta, inter- leukin-6, epidermal growth factor and trans-forming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 180(2):147-150
12. Mogi M et al (1994) Tumor necrosis factor- alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinso- nian patients. Neurosci Lett 165(1-2): 208-210
13. McGeer PL et al (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38(8):1285-1291
14. McGeer PL, Itagaki S, McGeer EG (1988) Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol 76(6):550-557
15. Imamura K et al (2003) Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson’s disease brains. Acta Neuropathol 106(6):518-526
16. Croisier E et al (2005) Microglial inflamma- tion in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J Neuroinflammation 2:14
17. Gerhard A et al (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis 21(2):404-412
18. Doorn KJ et al (2014) Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson inverted question marks disease patients. Acta Neuropathol Commun 2(1):90
19. Cheng HC, Ulane CM, Burke RE (2010) Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 67(6):715-725
20. Kirik D, Bjorklund A (2003) Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors. Trends Neurosci 26(7):386-392
21. Chesselet MF (2008) In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson’s disease? Exp Neurol 209(1):22-27
22. Schneider B, Zufferey R, Aebischer P (2008) Viral vectors, animal models and new therapies for Parkinson’s disease. Parkinsonism Relat Disord 14(Suppl 2):S169-S171
23. Ulusoy A et al (2008) In vivo gene delivery for development of mammalian models for Parkinson’s disease. Exp Neurol 209(1):89-100
24. Lindgren HS, Lelos MJ, Dunnett SB (2012) Do alpha-synuclein vector injections provide a better model of Parkinson’s disease than the classic 6-hydroxydopamine model? Exp Neurol 237(1):36-42
25. Low K, Aebischer P (2012) Use of viral vectors to create animal models for Parkinson’s disease. Neurobiol Dis 48(2):189-201
26. Van der Perren A, Van den Haute C, Baekelandt V (2015) Viral vector-based models of Parkinson’s disease. Curr Top Behav Neurosci 22:271-301
27. Polymeropoulos MH et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276(5321):2045-2047
28. Ibáñez P et al (2004) Causal relation between alpha-synuclein gene duplication and familial Parkinson’s disease. Lancet 364(9440):1169-1171
29. Kruger R et al (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat Genet 18(2):106-108
30. Singleton AB et al (2003) alpha-Synuclein locus triplication causes Parkinson’s disease. Science 302(5646):841
31. Gasser T, Hardy J, Mizuno Y (2011) Milestones in PD genetics. Mov Disord 26(6):1042-1048
32. Lees AJ, Hardy J, Revesz T (2009) Parkinson’s disease. Lancet 373(9680):2055-2066
33. Spillantini MG et al (1997) Alpha-synuclein in Lewy bodies. Nature 388(6645):839-840
34. Lo Bianco C et al (2002) alpha-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson’s disease. Proc Natl Acad Sci U S A 99(16):10813-10818
35. Kirik D et al (2002) Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 22(7):2780-2791
36. Klein RL et al (2002) Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. Hum Gene Ther 13(5):605-612
37. Gorbatyuk OS et al (2008) The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc Natl Acad Sci U S A 105(2):763-768
38. da Azeredo Silveira S et al (2009) Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson’s disease. Hum Mol Genet 18(5):872-887
39. McFarland NR et al (2009) Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. J Neuropathol Exp Neurol 68(5):515-524
40. Winner B et al (2011) In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A 108(10):4194-4199
41. Yamada M et al (2004) Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson’s disease. J Neurochem 91(2):451-461
42. Yamada M, Mizuno Y, Mochizuki H (2005) Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson’s disease. Hum Gene Ther 16(2):262-270
43. Ulusoy A et al (2010) Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology. Eur J Neurosci 32(3):409-422
44. Sanchez-Guajardo V et al (2010) Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathol- ogy in a rAAV based model of Parkinson’s disease. PLoS One 5(1):e8784
45. Decressac M et al (2011) GDNF fails to exert neuroprotection in a rat alpha-synuclein model of Parkinson’s disease. Brain 134(Pt 8):2302-2311
46. Decressac M et al (2012) Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of alpha- synuclein in midbrain dopamine neurons. Neurobiol Dis 45(3):939-953
47. Decressac M, Mattsson B, Bjorklund A (2012) Comparison of the behavioural and histological characteristics of the 6-OHDA and alpha- synuclein rat models of Parkinson’s disease. Exp Neurol 235(1):306-315
48. Mulcahy P et al (2012) Development and char- acterisation of a novel rat model of Parkinson’s disease induced by sequential intranigral administration of AAV-alpha-synuclein and the pesticide, rotenone. Neuroscience 203:170-179
49. Gombash SE et al (2013) Morphological and behavioral impact of AAV2/5-mediated over-expression of human wildtype alpha-synuclein in the rat nigrostriatal system. PLoS One 8(11):e81426
50. St. Martin JL et al (2007) Dopaminergic neu- ron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. J Neurochem 100(6):1449-1457
51. Theodore S et al (2008) Targeted overexpres- sion of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol 67(12):1149-1158
52. Oliveras-Salva M et al (2013) rAAV2/7 vector- mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration. Mol Neurodegener 8:44
53. Oliveras-Salva M et al (2014) Alpha-synuclein-induced neurodegeneration is exacerbated in PINK1 knockout mice. Neurobiol Aging 35(11):2625-2636
54. Kirik D et al (2003) Nigrostriatal alpha-synucleinopathy induced by viral vector- mediated overexpression of human Viral Vectors to Model PD 381 alpha-synuclein: a new primate model of Parkinson's disease. Proc Natl Acad Sci U S A 100(5):2884-2889
55. Eslamboli A et al (2007) Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain 130(Pt 3):799-815
56. Yasuda T et al (2007) Neuronal specificity of alpha-synuclein toxicity and effect of Parkin coexpression in primates. Neuroscience 144(2):743-753
57. Lo Bianco C et al (2004) Lentiviral nigral delivery of GDNF does not prevent neurode-generation in a genetic rat model of Parkinson’s disease. Neurobiol Dis 17(2):283-289
58. Lo Bianco C et al (2004) Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson’s disease. Proc Natl Acad Sci U S A 101(50):17510-17515
59. Lauwers E et al (2007) Non-invasive imaging of neuropathology in a rat model of alpha-synuclein overexpression. Neurobiol Aging 28(2):248-257
60. Lauwers E et al (2003) Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein. Brain Pathol 13(3): 364-372
61. Maingay M et al (2006) Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression. Neurobiol Dis 23(3):522-532
62. Chung CY et al (2009) Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J Neurosci 29(11):3365-3373
63. Koprich JB et al (2011) Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson’s disease produced by decreasing doses of alpha-synuclein. PLoS One 6(3):e17698
64. Barkholt P et al (2012) Long-term polarization of microglia upon alpha-synuclein overexpression in nonhuman primates. Neuroscience 208:85-96
65. Febbraro F et al (2013) Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson’s disease. Neurobiol Dis 56:47-58
66. Lundblad M et al (2012) Impaired neurotransmission caused by overexpression of alpha-synuclein in nigral dopamine neurons. Proc Natl Acad Sci U S A 109(9):3213-3219
67. Ulusoy A et al (2010) Viral vector-mediated overexpression of alpha-synuclein as a progressive model of Parkinson’s disease. Prog Brain Res 184:89-111
68. Sanchez-Guajardo V et al (2013) Neuroimmunological processes in Parkinson’s disease and their relation to alpha-synuclein: microglia as the referee between neuronal processes and peripheral immunity. ASN Neuro 5(2):113-139
69. Mata IF et al (2006) LRRK2 in Parkinson’s disease: protein domains and functional insights. Trends Neurosci 29(5):286-293
70. Giasson BI et al (2006) Biochemical and pathological characterization of Lrrk2. Ann Neurol 59(2):315-322
71. Paisan-Ruiz C et al (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron 44(4):595-600
72. Ross OA et al (2006) Lrrk2 and Lewy body disease. Ann Neurol 59(2):388-393
73. Zimprich A et al (2004) The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet 74(1):11-19
74. Cookson MR, Hardy J, Lewis PA (2008) Genetic neuropathology of Parkinson’s disease. Int J Clin Exp Pathol 1(3):217-231
75. Dusonchet J et al (2011) A rat model of progressive nigral neurodegeneration induced by the Parkinson’s disease-associated G2019S mutation in LRRK2. J Neurosci 31(3):907-912
76. Lee BD et al (2010) Inhibitors of leucinerich repeat kinase-2 protect against models of Parkinson’s disease. Nat Med 16(9):998-1000
77. Kitada T et al (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392(6676):605-608
78. Lucking CB et al (2000) Association between early-onset Parkinson’s disease and mutations in the parkin gene. N Engl J Med 342(21):1560-1567
79. Shimura H et al (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25(3):302-305
80. Takahashi H et al (1994) Familial juvenile parkinsonism: clinical and pathologic study in a family. Neurology 44(3 Pt 1):437-441
81. Dong Z et al (2003) Dopamine-dependent neurodegeneration in rats induced by viral vector-mediated overexpression of the parkin target protein, CDCrel-1. Proc Natl Acad Sci U S A 100(21):12438-12443
82. Kitao Y et al (2007) Pael receptor induces death of dopaminergic neurons in the substantia nigra via endoplasmic reticulum stress and dopamine toxicity, which is enhanced under condition of parkin inactivation. Hum Mol Genet 16(1):50-60
83. Dusonchet J et al (2009) Targeted overexpression of the parkin substrate Pael-R in the nigrostriatal system of adult rats to model Parkinson’s disease. Neurobiol Dis 35(1):32-41
84. Ko HS et al (2005) Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J Neurosci 25(35):7968-7978
85. Krenz A et al (2009) Aggregate formation and toxicity by wild-type and R621C synphilin-1 in the nigrostriatal system of mice using adenoviral vectors. J Neurochem 108(1):139-146
86. Hommel JD et al (2003) Local gene knock-down in the brain using viral-mediated RNA interference. Nat Med 9(12):1539-1544
87. Ulusoy A et al (2009) Dose optimization for long-term rAAV-mediated RNA interference in the nigrostriatal projection neurons. Mol Ther 17(9):1574-1584
88. Houlden H, Singleton AB (2012) The genet- ics and neuropathology of Parkinson’s disease. Acta Neuropathol 124(3):325-338
89. Trempe JF, Fon EA (2013) Structure and function of Parkin, PINK1, and DJ-1, the three musketeers of neuroprotection. Front Neurol 4:38
90. Haque ME et al (2012) Inactivation of Pink1 gene in vivo sensitizes dopamine-producing neurons to 1-methyl-4-phenyl-1,2,3,6-tetrahy- dropyridine (MPTP) and can be rescued by autosomal recessive Parkinson disease genes, Parkin or DJ-1. J Biol Chem 287(27): 23162-23170
91. Collier TJ, Kanaan NM, Kordower JH (2011) Ageing as a primary risk factor for Parkinson’s disease: evidence from studies of non-human primates. Nat Rev Neurosci 12(6):359-366
92. Polinski NK et al (2015) Recombinant adeno-associated virus 2/5-mediated gene transfer is reduced in the aged rat midbrain. Neurobiol Aging 36(2):1110-1120
93. Wu K et al (2004) The effects of rAAV2- mediated NGF gene delivery in adult and aged rats. Mol Ther 9(2):262-269
94. Klein RL et al (2010) Pronounced microgliosis and neurodegeneration in aged rats after tau gene transfer. Neurobiol Aging 31(12): 2091-2102